1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Genovate Biotechnology Co., Ltd.

Genovate Biotechnology Co., Ltd.

4130.TWO
Genovate Biotechnology Co., Ltd.TW flagTaipei Exchange
25.95
TWD
- -
- -
2.95BMarket Cap
Genovate Biotechnology Co., Ltd.
4130.TWO
(Taipei Exchange)

Recent

price

25.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.99
3.27
3.03
3.46
4.14
4.01
3.44
3.44
3.84
3.92
4.04
3.71
3.75
4.45
4.32
- -
3.89
Revenue per Share
0.36
0.55
0.53
0.4
0.63
0.39
0.33
1.25
0.49
0.29
0.33
- -
-0.11
0.25
0.22
- -
0.09
Basic EPS, GAAP
-0.03
0.48
0.12
0.76
0.42
-0.2
0.25
-0.06
0.22
0.13
0.51
-0.3
-0.19
0.43
0.2
- -
-0.14
Free Cash Flow per Basic Share
- -
- -
- -
0.25
0.25
0.42
0.42
0.3
0.68
0.25
0.41
0.37
0.32
0.16
0.14
- -
- -
Dividend per Share
7.51
7.94
8.75
8.91
9.19
9.11
8.89
9.86
9.8
10.11
10.37
10.35
10.25
9.33
10.12
- -
9.44
Book Value per Share
7.5
7.89
8.71
8.86
10.41
17.8
18.8
13.45
13.15
11.83
12.16
11.77
12.05
12.34
12.22
- -
10.86
Tangible Book Value per Share
101
101
115
115
115
119
119
119
119
119
117
117
117
119
118
- -
127
Basic Weighted Avg Shares
302
331
348
397
475
478
411
408
456
466
473
434
439
529
511
492
492
Sales/Revenue/Turnover
1.69
8.97
4.28
9.96
15.97
11.81
3.91
0.18
6.94
8.48
8.35
-0.27
-3.17
5.11
4.59
1.4
1.4
Operating Margin (%)
24
25
23
25
23
26
30
31
32
34
35
36
36
37
38
39
39
Depreciation Expense
36
56
61
46
73
46
39
149
58
34
39
- -
-12
29
26
12
12
Net Income, GAAP
9.52
8.86
8.02
12
11.21
20.04
9.37
6.78
9.52
16.27
4.97
89.57
- -
4.84
17.26
13.17
13.17
Effective Tax Rate (%)
11.98
16.79
17.42
11.5
15.26
9.73
9.54
36.49
12.69
7.31
8.19
0.09
-2.81
5.55
5.03
2.37
2.37
Profit Margin (%)
363
453
662
582
724
861
560
608
549
553
515
524
650
654
629
594
594
Working Capital
- -
- -
- -
- -
231
237
- -
- -
- -
- -
1
- -
1
- -
2
1
1
LT Debt
759
810
1,013
1,024
1,199
2,124
2,249
1,600
1,563
1,408
1,426
1,379
1,411
1,469
1,449
1,380
1,380
Total Equity
0.62
3.43
1.49
3.4
5.47
2.37
0.6
0.03
1.8
2.21
2.62
-0.01
- -
1.78
1.32
0.42
0.42
Return on Invested Capital (%)
4.85
7.12
6.7
4.5
6.27
3.93
3.41
12.51
4.93
2.89
3.21
0.03
- -
2.56
2.26
1.02
1.02
Return on Capital (%)
4.89
7.12
6.7
4.5
6.98
4.34
3.65
13.34
4.96
2.88
3.21
0.03
-1.02
2.54
2.23
0.98
0.98
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
117
117
117
Market Capitalization
2,251
2,918
3,396

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
751
716
719
Cash, Cash Equivalents & STI
493
466
482
Accounts Receivable, Net
88
75
74
Inventories
140
151
144
Total Current Liabilities
134
120
125
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.69%
-0.59%
-4.75%
Free Cash Flow
-131.75%
-150.43%
-174.25%
Net Income, GAAP
-374.1%
-783.33%
-54.54%
Sales/Revenue/Turnover
0.71%
1.28%
-3.61%
Total Cash Common Dividend
- -
-23.72%
-32.02%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
132
140
137
119
529
2024
139
127
126
118
511
2025
131
126
116
119
492

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.11
0.11
0.14
- -
0.25
2024
0.14
0.07
0.05
- -
0.22
2025
0.08
0.07
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.16
2024
- -
- -
- -
- -
0.14
2025
- -
- -
- -
- -
- -
Similar Companies
BioDelivery Sciences Intl, Inc. Wrrt (BDSIW)
Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS)
Gland Pharma Limited (GLAND.BO)
TTK Healthcare Limited (TTKHLTCARE.NS)
Zhejiang Zhenyuan Share Co., Ltd. (000705.SZ)
Orion Oyj (ORINY)
Business
Genovate Biotechnology Co., Ltd. (4130.TWO) engages in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates, with a focus on specialty drugs for the Taiwanese market; its core products encompass nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs including Livepro (entecavir), cardiovascular system drugs such as cilostazol formulations, acne drugs, antineoplastic drugs like Genetaxyl (paclitaxel injection), anti-diabetic drugs including DBPR108, healthcare foods and cosmetics; the company also provides clinical experimental testing services (CRO/GCP), technology export services and contract manufacturing compliant with PIC/S GMP and PMDA standards for sterile preparations. Founded in 1993 and headquartered at No. 1, First Industrial Road, Hukou Township, Hsinchu County, Taiwan, Genovate operates primarily in Taiwan with exports and partnerships extending to China, Japan, the US, Australia, Europe and New Zealand, employing approximately 191-195 staff and listing on the Taipei Exchange (TPEx) since 2012. Recent developments include plans announced in May 2024 to submit a New Drug Application (NDA) for PMR (cilostazol extended-release tablets) to the US FDA under the 505(b)(2) pathway in the second half of 2025 for intermittent claudication; in 2023, partner CSPC Pharmaceutical Group filed and had accepted an NDA for DBPR108 (DPP-4 inhibitor) with China's NMPA following Phase III trials; Synmosa Biopharma proposed acquiring a 30% stake for TWD 830 million; GVX171/GX17 (S-(+)-hydroxychloroquine enantiomer) received US FDA approval in 2022 for first-in-human trials targeting antiphospholipid syndrome; ongoing investments and joint ventures persist with NaviFUS for neuronavigation-guided focused ultrasound systems in CNS diseases via subsidiaries like Genovate NaviFUS (Australia), UniPharma for GX17, and historical ties to CSPC (2012 onward) and Otsuka for PMR in Asia-Pacific.